In the first half of this webinar, Dr. Dastjerdi will cover the epidemiology, clinical manifestations, diagnosis, treatment, corneal complications and prevention of reactivation of herpes simplex virus. In the second half, Dr. Sawant will present data on the Effect of a Second Betadine Exposure on Corneal Toxicity to Decrease Donor Tissue Fungal Bioburden—an abstract detailing the benefits of Eversight's rigorous infection prevention protocol at the time of tissue procurement.
Mohammad H. Dastjerdi, MD, is an ophthalmologist and Assistant Professor at Rutgers New Jersey Medical School with specialty training in cornea, external disease and refractive surgery. Dr. Dastjerdi earned his medical degree from Tehran University of Medical Sciences and completed an ophthalmology residency at Kansas University Medical Center. He finished a clinical fellowship in cornea and external diseases at Michigan Medicine's Kellogg Eye Center. He also completed a research fellowship at Harvard's Schepens Eye Research Institute at Mass. Eye and Ear.
As Director of Research at Eversight, Onkar B. Sawant, PhD, is responsible for all research and development activities, in addition to leading the Eversight Center for Vision and Eye Banking Research located in Cleveland. Dr. Sawant received a doctorate in biomedical sciences and masters in biotechnology from Texas A&M University. He completed a postdoctoral fellowship at the Cleveland Clinic Cole Eye Institute and was named an Emerging Vision Scientist by the National Alliance for Eye and Vision Research.